NATCOPHARM - IntraDay Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

IntraDay Trade Rating: 3.8

📊 Intraday Trading Analysis for NATCOPHARM

NATCOPHARM shows a value-driven setup with improving momentum, but short-term caution is warranted due to weak volume and resistance overhead.

✅ Bullish Fundamentals

P/E (9.11) vs Industry PE (34.0): Deeply undervalued.

PEG Ratio (0.07): Extremely attractive valuation relative to growth.

ROCE (32.8%) & ROE (28.0%): Excellent capital efficiency.

Debt-to-Equity (0.04): Virtually debt-free.

EPS (₹105): Strong earnings base.

MACD (16.0): Bullish crossover — momentum building.

⚠️ Technical & Sentiment Concerns

RSI (48.2): Neutral — not yet bullish.

Volume (7.2 lakh) < Avg Vol (15 lakh): Weak participation.

Price < 200-DMA (₹1,013): Still below long-term resistance.

FII Holding ↓ (-1.97%): Institutional selling pressure.

52w Index (30.5%): Underperforming relative to highs.

🔹 Optimal Intraday Strategy

📌 If Entering Fresh Today

Buy Zone: ₹945–₹950 (near 50-DMA support)

Profit Targets

Target 1: ₹970 (minor resistance)

Target 2: ₹985 (if volume improves midday)

Stop-Loss: ₹935 (below support and psychological level)

📌 If Already Holding Today

Exit Triggers

RSI drops below 46: Momentum weakening

MACD flattens or turns down

Price fails to hold above ₹950 by mid-session

Volume remains below 8 lakh with sideways price action

🧠 Final Thoughts

NATCOPHARM is a value-rich stock with improving technicals, making it a decent intraday candidate if volume picks up. Watch for a breakout above ₹970 to confirm strength. Otherwise, trade cautiously within the ₹945–₹985 range.

Want to scan for other pharma stocks with low PEG and strong MACD setups?

Edit in a page